DexCom, Inc. (NASDAQ:DXCM – Get a Free Report) was on the receiving end of unusually large options trades on Friday. Traders acquired 11,852 put options on the stock. This represents an increase of approximately 87% compared to the typical volume of 6,354 put options.

Insider transactions at DexCom

In related news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction on Thursday, March 28. The stock sold at an average price of $140.04, for a total transaction of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction on Thursday, March 28. The shares sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares of the company’s stock, valued at $9,618,227.28. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC website. Also, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction on Monday, June 10. The shares sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The explanation of this sale can be found here. Insiders sold 60,837 shares of the company’s stock worth $8,377,125 in the last quarter. Corporate insiders own 0.30% of the company’s shares.

Hedge funds weigh heavily on DexCom

Several hedge funds and other institutional investors have recently changed their holdings in the company. Crewe Advisors LLC bought a new position in DexCom in the first quarter worth approximately $29,000. DSM Capital Partners LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $28,000. Riverview Trust Co bought a new stake in DexCom worth $32,000 in the first quarter. Valley National Advisers Inc. increased its holdings in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company worth $30,000, after acquiring an additional 103 shares last quarter. Finally, MV Capital Management Inc. increased its stake in DexCom shares by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. 97.75% of the shares are held by institutional investors.

Wall Street analysts weigh in

A number of stock analysts have recently weighed in on the stock. Redburn Atlantic initiated coverage on shares of DexCom in a report on Thursday, May 30. They issued a “neutral” rating and a $130.00 price objective for the company. Canaccord Genuity Group raised their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26. Royal Bank of Canada initiated coverage on shares of DexCom in a report on Tuesday, March 12. They issued an “outperform” rating and a $165.00 price target on the stock. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Finally, Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong buy” rating in a report on Friday, April 26. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $140.94.

Check out our latest analysis on DexCom

DexCom Price Performance

NASDAQ DXCM opened at $115.95 on Friday. DexCom has a one-year low of $74.75 and a one-year high of $142.00. The stock has a 50-day moving average of $127.57 and a 200-day moving average of $125.81. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The company has a market cap of $46.11 billion, a price-to-earnings ratio of 74.81, a PEG ratio of 2.86, and a beta of 1.22.

DexCom (NASDAQ:DXCM – Get Free Report) last reported its quarterly results on Thursday, April 25. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, sell-side analysts predict that DexCom will post 1.78 earnings per share for the current year.

DexCom Company Profile

(Get a free report)

DexCom, Inc, a medical device company, focuses on the design, development and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company supplies its systems for use by people with diabetes, but also for use by healthcare providers. Products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which allows authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, which is designed to replace fingerstick blood glucose testing in diabetes treatment decisions.

Read further

Receive daily news and reviews for DexCom – Enter your email address below to receive a concise daily digest of the latest news and analyst ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.